Harris & Harris Group Notes NeuroMetrixApproval.

Business/Health Editors

NEW YORK--(BUSINESS WIRE)--July 26, 2000

Harris & Harris Group, Inc. (NASDAQ: HHGP) noted NeuroMetrix, Inc.'s (www.neurometrix.com) announcement today that it has received approval to affix the CE Mark, which will allow NeuroMetrix to market within

the European marketplace, to its NC-stat(TM) nerve conduction monitoring system. The NC-stat system, which has been available in the U.S. for approximately one year, diagnoses and monitors neuromuscular disorders of the hand and wrist, such as carpal tunnel syndrome. NeuroMetrix is a spin-off from the Harvard-MIT Division of Health Sciences and Technology.

The information contained in the NeuroMetrix press release was not independently verified by Harris & Harris Group, which takes no responsibility for its content nor for any actions that anyone may take in reaction to it.

Harris & Harris Group owns a fully diluted 15.91 percent equity interest in privately owned NeuroMetrix. In addition, on June 30, 2000, Harris & Harris Group increased its investment in NeuroMetrix by $750,000 in the form of a note convertible into equity at a price to be determined. Including this note, Harris & Harris Group valued its interest in NeuroMetrix on June 30, 2000, the most recent date on which it valued its holdings, at $6.7 million. As of that date, NeuroMetrix was Harris & Harris Group's most highly valued private equity investment.

Harris & Harris Group is a Business Development Company with 9,240,831 common shares issued and outstanding. Detailed information about Harris & Harris Group and its holdings can be found on its website at http://www.hhgp.com.

This press release may contain statements of a forward-looking nature relating to future events. Statements contained in this press release that are forward looking statements are intended to be made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to the inherent uncertainties in predicting future results and conditions. These statements reflect the Company's current beliefs, and a number of important factors could cause actual results to differ materially from those expressed in this press release. Please see the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission for a more detailed discussion of the risks and uncertainties associated with the Company's business, including but not limited to the risks and uncertainties associated with venture capital investing and other significant factors that could affect the Company's actual results. Except as otherwise required by Federal securities laws, Harris & Harris Group, Inc. undertakes no obligation to update or revise these forward looking statements to reflect new events or uncertainties.